Advanced Non Small Cell Lung Cancer with activating Epidermal Growth Factor Receptor mutation: First line treatment and beyond.
CONCLUSION: To date, in the light of the data from the FLAURA study, osimertinib represents the best first line option in NSCLC patients with EGFR activating mutations; EGFR-TKI plus chemotherapy combination therapies, even though interesting, must still be considered investigational.
PMID: 30520383 [PubMed - as supplied by publisher]
Source: Reviews on Recent Clinical Trials - Category: Cancer & Oncology Authors: Rocco D, Battiloro C, Gravara LD, Gridelli C Tags: Rev Recent Clin Trials Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Study